BobcatBio

BobcatBio is a clinical-stage biotechnology company developing RB-1355, a first-in-class cell therapy that harnesses the versatility and potent capabilities of patient-derived macrophages to induce robust targeted tumor-killing immune responses, while significantly reducing or eliminating the need for traditional cancer treatments such as chemotherapy, high-dose radiation, and surgery, thereby improving patient outcomes and quality of life.